'Notable Upside Options Positioning' in Nektar Therapeutics (NKTR) Highlights 'Speculative Bullish Bias' Over the Next Month -Susquehanna
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Up)Join SI Premium – FREE
Susquehanna options strategist Alison Edwards highlights speculative bullish options bias in Nektar Therapeutics (NASDAQ: NKTR), as an opening investor bought 5,000 Jan 65 Calls for $1.50. Rcent weeks have also seen notable upside positioning in the longer-dated May options.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Chevron (CVX) April weekly162.50 straddle into quarter results
- New York Community Bancorp (NYCB) April weekly option implied volatility into quarter results
Create E-mail Alert Related Categories
Options, Trader TalkRelated Entities
Susquehanna International Group of CompaniesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
